Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; Department of Urology, Anhui Medical University, Hefei, Anhui 230032, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China.
Department of Urology, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, PR China; Department of Urology, Shantou University Medical College, Shantou, Guangdong 515041, PR China; The Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics, Peking University Shenzhen Hospital, Institute of Urology of Shenzhen PKU-HKUST Medical Center, Shenzhen, Guangdong 518036, PR China.
Biomed Pharmacother. 2018 Jun;102:718-727. doi: 10.1016/j.biopha.2018.03.072. Epub 2018 Apr 5.
Renal cell carcinoma (RCC), a heterogeneous type of cancer originating from the nephron, occupies approximately 3.9% of new carcinomas, with an increasing incidence in the past two decades. The most common subtype of renal cell carcinoma is clear cell RCC (ccRCC). Though surgery and other treatments are applied to RCC, it has the highest recurrence rate and mortality rate among the genitourinary cancers. As the study progressed, miRNAs are found to be the biomarkers for tumor diagnosis, prognosis and the targets for tumor management.
In present study, RT-qPCR, wound scratch assay, cell proliferation assay, transwell assay and flow cytometry assay were performed to ascertain miR-566 expression level and its proliferation, migration and apoptosis in RCC. Moreover, we analyzed the relation between miR-566 expression and clinicopathological variables or overall survival from the 42 formalin-fixed paraffin-embedded (FFPE) renal cancer samples. We further evaluate prognostic values of miR-566 expression.
miR-566 is up-regulated in RCC tissue samples and renal carcinoma cell lines. miR-566 promotes cell proliferation, mobility and inhibits cell apoptosis in 786-O and ACHN cell lines. Cox proportional hazard regression analysis indicates that low expression of miR-566 patients have a remarkable longer overall survival in the univariate and multivariate analysis. The Kaplan-Meier survival curves show that the low expression of miR-566 patients have a remarkable longer overall survival.
The results of the current study demonstrate that oncogene miR-566 is a potential biomarker not only for diagnosis but also for prognosis for RCC.
肾细胞癌（RCC）是一种起源于肾单位的异质性癌症，约占新发癌症的 3.9%，在过去二十年中发病率呈上升趋势。肾细胞癌最常见的亚型是透明细胞 RCC（ccRCC）。尽管手术和其他治疗方法被应用于 RCC，但它在泌尿生殖系统癌症中的复发率和死亡率最高。随着研究的进展，miRNA 被发现是肿瘤诊断、预后的生物标志物，也是肿瘤治疗的靶点。
在本研究中，通过 RT-qPCR、划痕实验、细胞增殖实验、Transwell 实验和流式细胞术来确定 miR-566 在 RCC 中的表达水平及其对细胞增殖、迁移和凋亡的影响。此外，我们从 42 例福尔马林固定石蜡包埋（FFPE）肾癌细胞样本中分析了 miR-566 表达与临床病理变量或总生存期之间的关系。我们进一步评估了 miR-566 表达的预后价值。
miR-566 在 RCC 组织样本和肾癌细胞系中上调。miR-566 在 786-O 和 ACHN 细胞系中促进细胞增殖、迁移，并抑制细胞凋亡。Cox 比例风险回归分析表明，miR-566 低表达的患者在单因素和多因素分析中总生存期显著延长。Kaplan-Meier 生存曲线显示，miR-566 低表达的患者总生存期显著延长。
本研究结果表明，癌基因 miR-566 不仅是 RCC 诊断的潜在生物标志物，也是预后的潜在生物标志物。
